Equities analysts expect that Conatus Pharmaceuticals Inc (NASDAQ:CNAT) will announce sales of $8.63 million for the current quarter, Zacks Investment Research reports. Five analysts have made estimates for Conatus Pharmaceuticals’ earnings, with estimates ranging from $6.13 million to $10.00 million. Conatus Pharmaceuticals reported sales of $8.80 million during the same quarter last year, which indicates a negative year-over-year growth rate of 1.9%. The business is expected to announce its next earnings results on Wednesday, March 6th.

On average, analysts expect that Conatus Pharmaceuticals will report full year sales of $34.81 million for the current financial year, with estimates ranging from $32.30 million to $36.18 million. For the next year, analysts anticipate that the company will post sales of $41.87 million, with estimates ranging from $24.25 million to $80.80 million. Zacks Investment Research’s sales calculations are an average based on a survey of research analysts that cover Conatus Pharmaceuticals.

Several equities research analysts recently commented on the company. HC Wainwright reissued a “buy” rating on shares of Conatus Pharmaceuticals in a research note on Monday, November 5th. Oppenheimer set a $10.00 price target on Conatus Pharmaceuticals and gave the company a “buy” rating in a research note on Thursday, December 6th. Stifel Nicolaus cut Conatus Pharmaceuticals from a “buy” rating to a “hold” rating and set a $4.00 price target for the company. in a research note on Thursday, December 6th. ValuEngine cut Conatus Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, November 1st. Finally, SunTrust Banks lowered their price target on Conatus Pharmaceuticals to $12.00 and set a “buy” rating for the company in a research note on Thursday, December 6th. Three analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $8.50.

Shares of NASDAQ CNAT traded up $0.03 during trading hours on Wednesday, hitting $2.00. The stock had a trading volume of 13,413 shares, compared to its average volume of 568,730. The stock has a market cap of $60.82 million, a price-to-earnings ratio of -3.28 and a beta of 3.41. Conatus Pharmaceuticals has a 52 week low of $1.15 and a 52 week high of $7.95. The company has a debt-to-equity ratio of 0.83, a quick ratio of 2.39 and a current ratio of 2.39.

A number of institutional investors have recently made changes to their positions in the business. Creative Planning bought a new stake in Conatus Pharmaceuticals during the fourth quarter worth approximately $38,000. Hikari Power Ltd bought a new stake in Conatus Pharmaceuticals during the fourth quarter worth approximately $289,000. Virtu Financial LLC boosted its position in Conatus Pharmaceuticals by 94.6% during the third quarter. Virtu Financial LLC now owns 25,860 shares of the biotechnology company’s stock worth $150,000 after purchasing an additional 12,572 shares during the period. Artal Group S.A. bought a new stake in Conatus Pharmaceuticals during the third quarter worth approximately $2,900,000. Finally, BlackRock Inc. boosted its position in Conatus Pharmaceuticals by 13.4% during the third quarter. BlackRock Inc. now owns 1,623,958 shares of the biotechnology company’s stock worth $9,419,000 after purchasing an additional 191,287 shares during the period. 32.89% of the stock is owned by hedge funds and other institutional investors.

Conatus Pharmaceuticals Company Profile

Conatus Pharmaceuticals Inc, a biotechnology company, focuses on the development and commercialization of novel medicines for the treatment of liver diseases in the United States. Its product candidates include Emricasan, an orally active pan-caspase protease inhibitor that is in Phase IIb clinical trials for post-orthotopic liver transplant as a result of hepatitis C virus infection with sustained viral response; for patients with portal hypertension; for patients liver fibrosis caused by nonalcoholic steatohepatitis; and for liver function.

Read More: Bear Market – How and Why They Occur

Get a free copy of the Zacks research report on Conatus Pharmaceuticals (CNAT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Conatus Pharmaceuticals (NASDAQ:CNAT)

Receive News & Ratings for Conatus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Conatus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.